1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy

 
• By Neena Brizmohun

The first designation of 2018 under the European Medicines Agency’s PRIME scheme has gone to an advanced therapy for patients with the severe eye disorder, achromatopsia. In the meantime, most PRIME applications are still getting rejected.

Human eye
The EMA has accepted a gene therapy for an eye disorder onto PRIME • Source: Shutterstock

The European Medicines Agency has for the first time in three months accepted a product onto PRIME, its popular development support scheme for medicines addressing an unmet medical need – an investigational gene therapy for the eye disorder, achromatopsia.

MeiraGTx’s advanced therapy, A002, was one of six applications for designation as a priority medicine (PRIME) that the EMA’s Committee for Medicinal Products for Human Use (the CHMP) reviewed at its February meeting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 
• By Derrick Gingery, Sue Sutter, and Nielsen Hobbs

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.